Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are medications that are used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In Equatorial Guinea, the market for bronchodilator drugs has been growing steadily in recent years.
Customer preferences: Customers in Equatorial Guinea prefer bronchodilator drugs that are affordable and effective. They also prefer drugs that have minimal side effects. As a result, generic bronchodilator drugs are more popular in the market compared to branded drugs.
Trends in the market: The market for bronchodilator drugs in Equatorial Guinea has been growing steadily due to the increasing prevalence of respiratory diseases in the country. The government has also been investing in healthcare infrastructure, which has led to an increase in the availability of healthcare services across the country. This has made it easier for people to access bronchodilator drugs, which has contributed to the growth of the market.
Local special circumstances: Equatorial Guinea is a small country located in West Africa. The country has a relatively small population and a low GDP per capita. This means that affordability is a key consideration for customers when purchasing bronchodilator drugs. The government has also been working to improve access to healthcare services across the country, which has contributed to the growth of the market.
Underlying macroeconomic factors: The growth of the market for bronchodilator drugs in Equatorial Guinea is also influenced by macroeconomic factors such as GDP growth, inflation, and exchange rates. The country has been experiencing steady economic growth in recent years, which has led to an increase in disposable income for many people. This has made it easier for people to access healthcare services, including bronchodilator drugs. Additionally, the government has been working to stabilize the economy and reduce inflation, which has contributed to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
